Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy
Identifieur interne : 003C87 ( Main/Merge ); précédent : 003C86; suivant : 003C88Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy
Auteurs : Martin Köllensperger [Autriche] ; Nadia Stefanova [Autriche] ; Markus Reindl [Autriche] ; Werner Poewe [Autriche] ; Gregor K. Wenning [Autriche]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-02-15.
English descriptors
- KwdEn :
- Analysis of Variance, Animals, Apomorphine (pharmacology), Behavior, Animal (drug effects), Disease Models, Animal, Functional Laterality, Levodopa (therapeutic use), L‐dopa response, MSA‐P, Male, Multiple System Atrophy (chemically induced), Multiple System Atrophy (drug therapy), Multiple System Atrophy (pathology), Multiple System Atrophy (physiopathology), Oxidopamine, Parkinsonian Disorders (chemically induced), Parkinsonian Disorders (drug therapy), Parkinsonian Disorders (pathology), Parkinsonian Disorders (physiopathology), Rats, Rats, Wistar, Substantia Nigra (drug effects), Substantia Nigra (pathology), behavior.
- MESH :
- chemical , pharmacology : Apomorphine.
- chemically induced : Multiple System Atrophy, Parkinsonian Disorders.
- drug effects : Behavior, Animal, Substantia Nigra.
- drug therapy : Multiple System Atrophy, Parkinsonian Disorders.
- pathology : Multiple System Atrophy, Parkinsonian Disorders, Substantia Nigra.
- physiopathology : Multiple System Atrophy, Parkinsonian Disorders.
- chemical , therapeutic use : Levodopa.
- Analysis of Variance, Animals, Disease Models, Animal, Functional Laterality, Male, Oxidopamine, Rats, Rats, Wistar.
Abstract
The Parkinson variant of multiple system atrophy (MSA‐P) is a distinct atypical parkinsonian disorder with a loss of dopaminergic neurons comparable to that found in Parkinson's disease (PD). The additional loss of striatopallidal projections is thought to account for levodopa unresponsiveness in MSA‐P. Whereas histological features of MSA‐P have been successfully reproduced in the double lesion rat model, loss of levodopa responsiveness has so far not been demonstrated. In the current study, 6‐hydroxydopamine (6‐OHDA) induced unilateral lesions of the substantia nigra produced a marked contralateral forelimb stepping deficit, which improved significantly after challenge with levodopa (P < 0.001). This response was abolished by the subsequent striatal quinolinic acid (QA) lesion. In the cylinder test, the marked asymmetry observed after 6‐OHDA lesioning was reversed by levodopa to baseline levels. After QA, cylinder test performance under levodopa failed to reach baseline (P = 0.001) or 6‐OHDA + levodopa (P = 0.002) levels. Nigral cell loss (90% ± 5%) correlated with both stepping test (r = 0.608; P = 0.008) and cylinder test results (r = 0.656; P = 0.005). Lesion extent of the dorsal striatum correlated significantly with the loss of levodopa response (r = 0.593; P = 0.01) in the stepping test. These findings contribute further to the behavioral characterization of the double lesion rat model of MSA, improving its value in the evaluation of future neurorestorative strategies. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21251
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001776
- to stream Istex, to step Curation: 001776
- to stream Istex, to step Checkpoint: 001873
- to stream PubMed, to step Corpus: 002944
- to stream PubMed, to step Curation: 002944
- to stream PubMed, to step Checkpoint: 002737
- to stream Ncbi, to step Merge: 001995
- to stream Ncbi, to step Curation: 001995
- to stream Ncbi, to step Checkpoint: 001995
Links to Exploration step
ISTEX:C546EE867A4B96E0943262796E2A723667BD15F2Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy</title><author><name sortKey="Kollensperger, Martin" sort="Kollensperger, Martin" uniqKey="Kollensperger M" first="Martin" last="Köllensperger">Martin Köllensperger</name></author><author><name sortKey="Stefanova, Nadia" sort="Stefanova, Nadia" uniqKey="Stefanova N" first="Nadia" last="Stefanova">Nadia Stefanova</name></author><author><name sortKey="Reindl, Markus" sort="Reindl, Markus" uniqKey="Reindl M" first="Markus" last="Reindl">Markus Reindl</name></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><country>Autriche</country><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C546EE867A4B96E0943262796E2A723667BD15F2</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21251</idno><idno type="url">https://api.istex.fr/document/C546EE867A4B96E0943262796E2A723667BD15F2/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001776</idno><idno type="wicri:Area/Istex/Curation">001776</idno><idno type="wicri:Area/Istex/Checkpoint">001873</idno><idno type="wicri:doubleKey">0885-3185:2007:Kollensperger M:loss:of:dopaminergic</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:17149724</idno><idno type="wicri:Area/PubMed/Corpus">002944</idno><idno type="wicri:Area/PubMed/Curation">002944</idno><idno type="wicri:Area/PubMed/Checkpoint">002737</idno><idno type="wicri:Area/Ncbi/Merge">001995</idno><idno type="wicri:Area/Ncbi/Curation">001995</idno><idno type="wicri:Area/Ncbi/Checkpoint">001995</idno><idno type="wicri:doubleKey">0885-3185:2007:Kollensperger M:loss:of:dopaminergic</idno><idno type="wicri:Area/Main/Merge">003C87</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy</title><author><name sortKey="Kollensperger, Martin" sort="Kollensperger, Martin" uniqKey="Kollensperger M" first="Martin" last="Köllensperger">Martin Köllensperger</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Clinical Department of Neurology, Innsbruck Medical University</wicri:regionArea><wicri:noRegion>Innsbruck Medical University</wicri:noRegion></affiliation></author><author><name sortKey="Stefanova, Nadia" sort="Stefanova, Nadia" uniqKey="Stefanova N" first="Nadia" last="Stefanova">Nadia Stefanova</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Clinical Department of Neurology, Innsbruck Medical University</wicri:regionArea><wicri:noRegion>Innsbruck Medical University</wicri:noRegion></affiliation></author><author><name sortKey="Reindl, Markus" sort="Reindl, Markus" uniqKey="Reindl M" first="Markus" last="Reindl">Markus Reindl</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Clinical Department of Neurology, Innsbruck Medical University</wicri:regionArea><wicri:noRegion>Innsbruck Medical University</wicri:noRegion></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Clinical Department of Neurology, Innsbruck Medical University</wicri:regionArea><wicri:noRegion>Innsbruck Medical University</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Clinical Department of Neurology, Innsbruck Medical University</wicri:regionArea><wicri:noRegion>Innsbruck Medical University</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-02-15">2007-02-15</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="353">353</biblScope><biblScope unit="page" to="358">358</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">C546EE867A4B96E0943262796E2A723667BD15F2</idno><idno type="DOI">10.1002/mds.21251</idno><idno type="ArticleID">MDS21251</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analysis of Variance</term><term>Animals</term><term>Apomorphine (pharmacology)</term><term>Behavior, Animal (drug effects)</term><term>Disease Models, Animal</term><term>Functional Laterality</term><term>Levodopa (therapeutic use)</term><term>L‐dopa response</term><term>MSA‐P</term><term>Male</term><term>Multiple System Atrophy (chemically induced)</term><term>Multiple System Atrophy (drug therapy)</term><term>Multiple System Atrophy (pathology)</term><term>Multiple System Atrophy (physiopathology)</term><term>Oxidopamine</term><term>Parkinsonian Disorders (chemically induced)</term><term>Parkinsonian Disorders (drug therapy)</term><term>Parkinsonian Disorders (pathology)</term><term>Parkinsonian Disorders (physiopathology)</term><term>Rats</term><term>Rats, Wistar</term><term>Substantia Nigra (drug effects)</term><term>Substantia Nigra (pathology)</term><term>behavior</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Apomorphine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Multiple System Atrophy</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior, Animal</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Multiple System Atrophy</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Multiple System Atrophy</term><term>Parkinsonian Disorders</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Multiple System Atrophy</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term><term>Animals</term><term>Disease Models, Animal</term><term>Functional Laterality</term><term>Male</term><term>Oxidopamine</term><term>Rats</term><term>Rats, Wistar</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The Parkinson variant of multiple system atrophy (MSA‐P) is a distinct atypical parkinsonian disorder with a loss of dopaminergic neurons comparable to that found in Parkinson's disease (PD). The additional loss of striatopallidal projections is thought to account for levodopa unresponsiveness in MSA‐P. Whereas histological features of MSA‐P have been successfully reproduced in the double lesion rat model, loss of levodopa responsiveness has so far not been demonstrated. In the current study, 6‐hydroxydopamine (6‐OHDA) induced unilateral lesions of the substantia nigra produced a marked contralateral forelimb stepping deficit, which improved significantly after challenge with levodopa (P < 0.001). This response was abolished by the subsequent striatal quinolinic acid (QA) lesion. In the cylinder test, the marked asymmetry observed after 6‐OHDA lesioning was reversed by levodopa to baseline levels. After QA, cylinder test performance under levodopa failed to reach baseline (P = 0.001) or 6‐OHDA + levodopa (P = 0.002) levels. Nigral cell loss (90% ± 5%) correlated with both stepping test (r = 0.608; P = 0.008) and cylinder test results (r = 0.656; P = 0.005). Lesion extent of the dorsal striatum correlated significantly with the loss of levodopa response (r = 0.593; P = 0.01) in the stepping test. These findings contribute further to the behavioral characterization of the double lesion rat model of MSA, improving its value in the evaluation of future neurorestorative strategies. © 2006 Movement Disorder Society</div></front></TEI><double doi="10.1002/mds.21251"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy</title><author><name sortKey="Kollensperger, Martin" sort="Kollensperger, Martin" uniqKey="Kollensperger M" first="Martin" last="Köllensperger">Martin Köllensperger</name></author><author><name sortKey="Stefanova, Nadia" sort="Stefanova, Nadia" uniqKey="Stefanova N" first="Nadia" last="Stefanova">Nadia Stefanova</name></author><author><name sortKey="Reindl, Markus" sort="Reindl, Markus" uniqKey="Reindl M" first="Markus" last="Reindl">Markus Reindl</name></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><country>Autriche</country><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C546EE867A4B96E0943262796E2A723667BD15F2</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21251</idno><idno type="url">https://api.istex.fr/document/C546EE867A4B96E0943262796E2A723667BD15F2/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001776</idno><idno type="wicri:Area/Istex/Curation">001776</idno><idno type="wicri:Area/Istex/Checkpoint">001873</idno><idno type="wicri:doubleKey">0885-3185:2007:Kollensperger M:loss:of:dopaminergic</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy</title><author><name sortKey="Kollensperger, Martin" sort="Kollensperger, Martin" uniqKey="Kollensperger M" first="Martin" last="Köllensperger">Martin Köllensperger</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Clinical Department of Neurology, Innsbruck Medical University</wicri:regionArea><wicri:noRegion>Innsbruck Medical University</wicri:noRegion></affiliation></author><author><name sortKey="Stefanova, Nadia" sort="Stefanova, Nadia" uniqKey="Stefanova N" first="Nadia" last="Stefanova">Nadia Stefanova</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Clinical Department of Neurology, Innsbruck Medical University</wicri:regionArea><wicri:noRegion>Innsbruck Medical University</wicri:noRegion></affiliation></author><author><name sortKey="Reindl, Markus" sort="Reindl, Markus" uniqKey="Reindl M" first="Markus" last="Reindl">Markus Reindl</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Clinical Department of Neurology, Innsbruck Medical University</wicri:regionArea><wicri:noRegion>Innsbruck Medical University</wicri:noRegion></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Clinical Department of Neurology, Innsbruck Medical University</wicri:regionArea><wicri:noRegion>Innsbruck Medical University</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K." last="Wenning">Gregor K. Wenning</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Clinical Department of Neurology, Innsbruck Medical University</wicri:regionArea><wicri:noRegion>Innsbruck Medical University</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-02-15">2007-02-15</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="353">353</biblScope><biblScope unit="page" to="358">358</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">C546EE867A4B96E0943262796E2A723667BD15F2</idno><idno type="DOI">10.1002/mds.21251</idno><idno type="ArticleID">MDS21251</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>L‐dopa response</term><term>MSA‐P</term><term>behavior</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The Parkinson variant of multiple system atrophy (MSA‐P) is a distinct atypical parkinsonian disorder with a loss of dopaminergic neurons comparable to that found in Parkinson's disease (PD). The additional loss of striatopallidal projections is thought to account for levodopa unresponsiveness in MSA‐P. Whereas histological features of MSA‐P have been successfully reproduced in the double lesion rat model, loss of levodopa responsiveness has so far not been demonstrated. In the current study, 6‐hydroxydopamine (6‐OHDA) induced unilateral lesions of the substantia nigra produced a marked contralateral forelimb stepping deficit, which improved significantly after challenge with levodopa (P < 0.001). This response was abolished by the subsequent striatal quinolinic acid (QA) lesion. In the cylinder test, the marked asymmetry observed after 6‐OHDA lesioning was reversed by levodopa to baseline levels. After QA, cylinder test performance under levodopa failed to reach baseline (P = 0.001) or 6‐OHDA + levodopa (P = 0.002) levels. Nigral cell loss (90% ± 5%) correlated with both stepping test (r = 0.608; P = 0.008) and cylinder test results (r = 0.656; P = 0.005). Lesion extent of the dorsal striatum correlated significantly with the loss of levodopa response (r = 0.593; P = 0.01) in the stepping test. These findings contribute further to the behavioral characterization of the double lesion rat model of MSA, improving its value in the evaluation of future neurorestorative strategies. © 2006 Movement Disorder Society</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy.</title><author><name sortKey="Kollensperger, Martin" sort="Kollensperger, Martin" uniqKey="Kollensperger M" first="Martin" last="Köllensperger">Martin Köllensperger</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Department of Neurology, Innsbruck Medical University, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Clinical Department of Neurology, Innsbruck Medical University</wicri:regionArea><wicri:noRegion>Innsbruck Medical University</wicri:noRegion></affiliation></author><author><name sortKey="Stefanova, Nadia" sort="Stefanova, Nadia" uniqKey="Stefanova N" first="Nadia" last="Stefanova">Nadia Stefanova</name></author><author><name sortKey="Reindl, Markus" sort="Reindl, Markus" uniqKey="Reindl M" first="Markus" last="Reindl">Markus Reindl</name></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><country>Autriche</country><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K" last="Wenning">Gregor K. Wenning</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="doi">10.1002/mds.21251</idno><idno type="RBID">pubmed:17149724</idno><idno type="pmid">17149724</idno><idno type="wicri:Area/PubMed/Corpus">002944</idno><idno type="wicri:Area/PubMed/Curation">002944</idno><idno type="wicri:Area/PubMed/Checkpoint">002737</idno><idno type="wicri:Area/Ncbi/Merge">001995</idno><idno type="wicri:Area/Ncbi/Curation">001995</idno><idno type="wicri:Area/Ncbi/Checkpoint">001995</idno><idno type="wicri:doubleKey">0885-3185:2007:Kollensperger M:loss:of:dopaminergic</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy.</title><author><name sortKey="Kollensperger, Martin" sort="Kollensperger, Martin" uniqKey="Kollensperger M" first="Martin" last="Köllensperger">Martin Köllensperger</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Department of Neurology, Innsbruck Medical University, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Clinical Department of Neurology, Innsbruck Medical University</wicri:regionArea><wicri:noRegion>Innsbruck Medical University</wicri:noRegion></affiliation></author><author><name sortKey="Stefanova, Nadia" sort="Stefanova, Nadia" uniqKey="Stefanova N" first="Nadia" last="Stefanova">Nadia Stefanova</name></author><author><name sortKey="Reindl, Markus" sort="Reindl, Markus" uniqKey="Reindl M" first="Markus" last="Reindl">Markus Reindl</name></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><country>Autriche</country><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Wenning, Gregor K" sort="Wenning, Gregor K" uniqKey="Wenning G" first="Gregor K" last="Wenning">Gregor K. Wenning</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analysis of Variance</term><term>Animals</term><term>Apomorphine (pharmacology)</term><term>Behavior, Animal (drug effects)</term><term>Disease Models, Animal</term><term>Functional Laterality</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Multiple System Atrophy (chemically induced)</term><term>Multiple System Atrophy (drug therapy)</term><term>Multiple System Atrophy (pathology)</term><term>Multiple System Atrophy (physiopathology)</term><term>Oxidopamine</term><term>Parkinsonian Disorders (chemically induced)</term><term>Parkinsonian Disorders (drug therapy)</term><term>Parkinsonian Disorders (pathology)</term><term>Parkinsonian Disorders (physiopathology)</term><term>Rats</term><term>Rats, Wistar</term><term>Substantia Nigra (drug effects)</term><term>Substantia Nigra (pathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Apomorphine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Multiple System Atrophy</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior, Animal</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Multiple System Atrophy</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Multiple System Atrophy</term><term>Parkinsonian Disorders</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Multiple System Atrophy</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term><term>Animals</term><term>Disease Models, Animal</term><term>Functional Laterality</term><term>Male</term><term>Oxidopamine</term><term>Rats</term><term>Rats, Wistar</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The Parkinson variant of multiple system atrophy (MSA-P) is a distinct atypical parkinsonian disorder with a loss of dopaminergic neurons comparable to that found in Parkinson's disease (PD). The additional loss of striatopallidal projections is thought to account for levodopa unresponsiveness in MSA-P. Whereas histological features of MSA-P have been successfully reproduced in the double lesion rat model, loss of levodopa responsiveness has so far not been demonstrated. In the current study, 6-hydroxydopamine (6-OHDA) induced unilateral lesions of the substantia nigra produced a marked contralateral forelimb stepping deficit, which improved significantly after challenge with levodopa (P < 0.001). This response was abolished by the subsequent striatal quinolinic acid (QA) lesion. In the cylinder test, the marked asymmetry observed after 6-OHDA lesioning was reversed by levodopa to baseline levels. After QA, cylinder test performance under levodopa failed to reach baseline (P = 0.001) or 6-OHDA + levodopa (P = 0.002) levels. Nigral cell loss (90% +/- 5%) correlated with both stepping test (r = 0.608; P = 0.008) and cylinder test results (r = 0.656; P = 0.005). Lesion extent of the dorsal striatum correlated significantly with the loss of levodopa response (r = 0.593; P = 0.01) in the stepping test. These findings contribute further to the behavioral characterization of the double lesion rat model of MSA, improving its value in the evaluation of future neurorestorative strategies.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C87 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 003C87 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:C546EE867A4B96E0943262796E2A723667BD15F2
|texte= Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy
}}
| This area was generated with Dilib version V0.6.23. |  |